In early October, I looked at the prospects for Teva (TEVA) in an articletitled, "Copaxone competition comes at the worst time". Shares were under pressure following the launch of a competing drug by Mylan (MYL) in a move which could cut operating earnings by $1.3 billion a year.
The timing of this news has been very unfortunate as Teva has already been under a lot of pressure after the acquisition of the generics business from Allergan (NYSE:AGN) backfired, and put a lot of (financial) pressure on the company. The company continues to aggressively tackle its challenges, including big job cuts, a complete elimination of the dividend and further asset sales as the situation remains highly challenged.

